Eravacycline Dosage

Medically reviewed by Drugs.com. Last updated on Nov 3, 2020.

Usual Adult Dose for Intraabdominal Infection

1 mg/kg IV every 12 hours for 4 to 14 days

Use: For the treatment of complicated intraabdominal infections due to susceptible Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, K oxytoca, Enterococcus faecalis, E faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, Parabacteroides distasonis

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild to moderate liver dysfunction (Child-Pugh A and B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C):
-First day: 1 mg/kg IV every 12 hours
-Starting on second day: 1 mg/kg IV every 24 hours
Total duration of therapy: 4 to 14 days

Dose Adjustments

Coadministration with a weak or moderate CYP450 3A inducer: No adjustment recommended.
Coadministration with a strong CYP450 3A inducer: 1.5 mg/kg IV every 12 hours
Total duration of therapy: 4 to 14 days

Precautions

CONTRAINDICATIONS:
Known hypersensitivity to the active component, tetracycline-class antibacterial agents, or any of the ingredients

Safety and efficacy have not been established in patients younger than 18 years; this drug is not recommended for use in patients younger than 8 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Comments:
-Significant removal via hemodialysis is not expected.

Other Comments

Administration advice:
-Administer via IV infusion over about 60 minutes; administer through a dedicated line or through a Y-site.
-If the same IV line is used for sequential infusion of several drugs, flush the line before and after infusion of this drug with 0.9% Sodium Chloride Injection, USP.
-Must infuse reconstituted and diluted solutions within 6 hours if stored at room temperature or 24 hours if stored refrigerated.
-Use severity and location of infection and patient clinical response to guide duration of therapy.

Storage requirements:
-Powder (prior to reconstitution): Store vials at 2C to 8C (36F to 46F); keep vial in carton until use.
-Reconstituted and diluted solutions: May store at room temperature (not to exceed 25C [77F]) or refrigerated at 2C to 8C (36F to 46F); must be infused within 6 or 24 hours, respectively; do not freeze.

Reconstitution/preparation techniques:
-Reconstitute vial(s) with Sterile Water for Injection, USP; swirl gently to dissolve.
-The reconstituted solution must be diluted further in a 0.9% Sodium Chloride Injection, USP infusion bag prior to IV infusion.
-The manufacturer product information should be consulted.

IV compatibility:
-Compatible IV solutions: 0.9% Sodium Chloride Injection, USP
-Compatibility with other drugs and infusion solutions not established.
-This drug should not be mixed with other drugs or added to solutions containing other drugs.

General:
-This drug is not indicated for the treatment of complicated urinary tract infections.
-To reduce the development of drug-resistant organisms and maintain effective therapy, this drug should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
-Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Patient advice:
-Avoid missing doses and complete the entire course of therapy.
-Notify healthcare provider immediately if you become pregnant during therapy.
-Contact healthcare provider at once if watery and bloody stools (with or without stomach cramps and fever) develop.

Frequently asked questions

• What type of drug is Xerava?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer